0000899243-22-018011.txt : 20220513 0000899243-22-018011.hdr.sgml : 20220513 20220513162853 ACCESSION NUMBER: 0000899243-22-018011 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220510 FILED AS OF DATE: 20220513 DATE AS OF CHANGE: 20220513 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Greenberg Bruce CENTRAL INDEX KEY: 0001928391 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36332 FILM NUMBER: 22923212 MAIL ADDRESS: STREET 1: C/O ALDEYRA THERAPEUTICS, INC. STREET 2: 131 HARTWELL AVENUE, SUITE 320 CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aldeyra Therapeutics, Inc. CENTRAL INDEX KEY: 0001341235 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 131 HARTWELL AVENUE STREET 2: SUITE 320 CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 781-761-4904 MAIL ADDRESS: STREET 1: 131 HARTWELL AVENUE STREET 2: SUITE 320 CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: Aldexa Therapeutics, Inc. DATE OF NAME CHANGE: 20130102 FORMER COMPANY: FORMER CONFORMED NAME: Neuron Systems Inc DATE OF NAME CHANGE: 20051012 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2022-05-10 0 0001341235 Aldeyra Therapeutics, Inc. ALDX 0001928391 Greenberg Bruce C/O ALDEYRA THERAPEUTICS, INC. 131 HARTWELL AVENUE, SUITE 320 LEXINGTON MA 02421 0 1 0 0 See Remarks Common Stock 7813 D Employee Stock Option (Right to Buy) 5.32 2029-12-11 Common Stock 45000 D Employee Stock Option (Right to Buy) 3.57 2030-03-04 Common Stock 20000 D Employee Stock Option (Right to Buy) 12.24 2031-03-21 Common Stock 58477 D Employee Stock Option (Right to Buy) 11.28 2031-04-17 Common Stock 29239 D Employee Stock Option (Right to Buy) 3.50 2032-03-03 Common Stock 100000 D Employee Stock Option (Right to Buy) 4.52 2032-03-30 Common Stock 73156 D The shares subject to this option shall vest over 4 years of service following December 12, 2019 with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter. The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2020. The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2021. The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2022. Interim Chief Financial Officer /s/ Bruce Greenberg 2022-05-13